Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

535 questions in 56 reviews · Hypertension

current versions

No studies 37 · 6.9%Ungraded 34 · 6.4%Very low 91 · 17%Low 161 · 30.1%Moderate 136 · 25.4%High 76 · 14.2%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Intervention NR 0.3 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	17 studies · 2567 participants	High
Intervention NR 0.4 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	10 studies · 2715 participants	High
Intervention NR 0.8 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	5 studies · 1938 participants	High
Intervention NR CI: confidence interval · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cerivastatin dose · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR 0.05 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	2 studies · 504 participants	Very low
Intervention NR 0.05 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	5 studies · 1811 participants	High
Intervention NR 0.1 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	4 studies · 731 participants	Moderate
Intervention NR 0.2 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	5 studies · 780 participants	Moderate
Intervention NR 0.3 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	8 studies · 1303 participants	Moderate
Intervention NR 0.4 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	6 studies · 1969 participants	Moderate
Intervention NR 0.8 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	4 studies · 1880 participants	Moderate
Intervention NR CI: confidence interval · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
All doses of cerivastatin vs placebo Withdrawals due to adverse events · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	RR 1.09 [0.68, 1.74]	11 studies · 6570 participants	Very low
Intervention NR 0.1 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	11 studies · 2327 participants	High
Intervention NR 0.2 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	15 studies · 2498 participants	High
Intervention NR 0.3 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	19 studies · 3020 participants	High
Intervention NR 0.4 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	13 studies · 3080 participants	High
Intervention NR 0.8 mg/d · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	6 studies · 2560 participants	High
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cerivastatin dose · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Renin inhibitors vs ACE inhibitors All‐cause mortality · people with primary hypertension Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension (2020) · Cochrane	RR 1.05 [0.93, 1.18]	5 studies · 5962 participants	Low
Renin inhibitors vs ACE inhibitors Fatal or non‐fatal myocardial infarction · people with primary hypertension Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension (2020) · Cochrane	RR 0.86 [0.22, 3.39]	2 studies · 957 participants	Very low
Renin inhibitors vs ACE inhibitors Adverse events · people with primary hypertension Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension (2020) · Cochrane	RR 0.98 [0.93, 1.03]	10 studies · 6007 participants	Moderate
Renin inhibitors vs ACE inhibitors Fatal or non‐fatal serious adverse events · people with primary hypertension Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension (2020) · Cochrane	RR 1.21 [0.89, 1.64]	10 studies · 6007 participants	Low
Renin inhibitors vs ACE inhibitors Withdrawal due to adverse effects (WDAE) · people with primary hypertension Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension (2020) · Cochrane	RR 0.85 [0.68, 1.06]	10 studies · 6008 participants	Low
Renin inhibitors vs ACE inhibitors SBP · people with primary hypertension Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension (2020) · Cochrane	no estimate extracted	9 studies · 5001 participants	Low
Renin inhibitors vs ACE inhibitors DBP · people with primary hypertension Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension (2020) · Cochrane	no estimate extracted	9 studies · 5001 participants	Low
Discontinuation by no treatment/placebo of antihypertensives vs continuation All‐cause mortality · Older adults, 50 years and older Withdrawal of antihypertensive drugs in older people (2020) · Cochrane	OR 2.08 [0.79, 5.46]	4 studies · 630 participants	Low
Discontinuation by no treatment/placebo of antihypertensives vs continuation Myocardial infarction (fatal and nonfatal) · Older adults, 50 years and older Withdrawal of antihypertensive drugs in older people (2020) · Cochrane	OR 1.86 [0.19, 17.98]	2 studies · 447 participants	Very low
Discontinuation by no treatment/placebo of antihypertensives vs continuation Hospitalisation · Older adults, 50 years and older Withdrawal of antihypertensive drugs in older people (2020) · Cochrane	OR 0.83 [0.33, 2.1]	1 study · 385 participants	Low
Discontinuation by no treatment/placebo of antihypertensives vs continuation Stroke (fatal + nonfatal + TIA) · Older adults, 50 years and older Withdrawal of antihypertensive drugs in older people (2020) · Cochrane	OR 1.44 [0.25, 8.35]	3 studies · 524 participants	Low
Discontinuation by no treatment/placebo of antihypertensives vs continuation Systolic blood pressure · Older adults, 50 years and older Withdrawal of antihypertensive drugs in older people (2020) · Cochrane	no estimate extracted	5 studies · 767 participants	Low
Discontinuation by no treatment/placebo of antihypertensives vs continuation Diastolic blood pressure: range 12 weeks to 12 months · Older adults, 50 years and older Withdrawal of antihypertensive drugs in older people (2020) · Cochrane	no estimate extracted	5 studies · 768 participants	Low
Discontinuation by no treatment/placebo of antihypertensives vs continuation Adverse drug reactions and adverse drug withdrawal reactions (adverse reactions) · Older adults, 50 years and older Withdrawal of antihypertensive drugs in older people (2020) · Cochrane	no estimate extracted	3 studies · 245 participants	Very low
Discontinuation by no treatment/placebo of antihypertensives vs continuation Falls ‐ not reported · Older adults, 50 years and older Withdrawal of antihypertensive drugs in older people (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR pitavastatin dose · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR mg/day · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	7 studies · 477 participants	High
Intervention NR CI: Confidence interval · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Pitavastatin dose · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR mg/day · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	8 studies · 673 participants	High
Intervention NR mg/day · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	26 studies · 2035 participants	High
Intervention NR mg/day · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	6 studies · 424 participants	High
Intervention NR CI: Confidence interval · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	NR	No studies
Intervention NR mg/day · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	10 studies · 759 participants	High
Intervention NR mg/day · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	36 studies · 3847 participants	High
Intervention NR mg/day · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane	no estimate extracted	7 studies · 469 participants	High